fludarabine monophosphate + melphalan + bortezomib

The combination of fludarabine monophosphate, melphalan, and bortezomib is a chemotherapy regimen used primarily in the treatment of hematological malignancies, particularly multiple myeloma. This combination has been studied in clinical trials, including a phase 1 study as conditioning therapy before allogeneic hematopoietic stem cell transplantation for patients with high-risk or refractory multiple myeloma[3]. ## Mechanism of Action This combination leverages the distinct mechanisms of each component: - **Fludarabine monophosphate**: A purine analog antimetabolite that inhibits DNA synthesis[4]. It interferes with DNA polymerase alpha, ribonucleotide reductase, and DNA primase, resulting in the inhibition of DNA synthesis in cancer cells[4]. - **Melphalan**: An alkylating agent that works by cross-linking DNA strands, preventing cell division. - **Bortezomib**: A proteasome inhibitor that works by reversibly inhibiting the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells[2]. It was the first anticancer proteasome inhibitor approved by the FDA under the trade name VELCADE[2]. ## Clinical Applications The combination has been studied in clinical trials for: 1. Conditioning regimen before allogeneic hematopoietic stem cell transplantation for high-risk or refractory multiple myeloma patients[3] 2. Treatment of relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma (when combined with rituximab)[1] In the phase 1 study mentioned in the search results, the combination showed promising results with manageable toxicity profiles. The median overall survival and progression-free survival varied depending on whether total marrow irradiation (TMI) was included in the regimen[3]. ## Toxicity Profile Common adverse effects associated with this combination include: - Myelosuppression (reduction in bone marrow activity) - Neuropathy - Dose-limiting toxicities that required careful dose adjustments in clinical trials[3] The maximum tolerated dose established in one study was fludarabine 25 mg/m² on days 1-3, bortezomib 1.3 mg/m² on days 1, 4, 8, 11, with rituximab 375 mg/m² on day 1 administered every 21 days[1].